ConductScience.org, home

Paper39604266

A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.

Holt BD and 9 others. Mol Ther, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. Papers, record 39604266. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39604266

Download JSON
Instrument
Rotarod Test18 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.
PubMed
Journal
Mol Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.69, provisional
iCite
Revised in PubMed
2026-10-07
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Holt BDBryce D
2Elliott SJSamuel J
3Meyer RRebecca
4Reyes DDaniela
5O'Neil KKaryn
6Druzina ZZhanna
7Kulkarni SSwapnil
8Thurberg BLBeth L
9Nadler SGSteven G
10Pederson BABartholomew A

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Glycogen Storage Disease Type IIMajor topic
GlycogenMajor topic
Disease Models, AnimalMajor topic
RNA, Small InterferingMajor topic
Animals
Mice
Humans
Receptors, Transferrin
Antigens, CD
Muscle, Skeletal
Glycogen Synthase

Source PubMed

Download CSV of topics

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118232732A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice.PLoS Med2008https://conductscience.org/library/papers/18232732PubMed
29668092Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II.J Biol Chem1998https://conductscience.org/library/papers/9668092PubMed
322992140Immune modulation in Pompe disease treated with enzyme replacement therapy.Expert Rev Clin Immunol2012https://conductscience.org/library/papers/22992140PubMed
440268518Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease.Clin Transl Med2025https://conductscience.org/library/papers/40268518PubMed
511283248Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL.Mol Cell Biol2001https://conductscience.org/library/papers/11283248PubMed
634506219Regulation and role of glycophagy in skeletal muscle energy metabolism.Autophagy2022https://conductscience.org/library/papers/34506219PubMed
720865334Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience.J Inherit Metab Dis2010https://conductscience.org/library/papers/20865334PubMed
817151339Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.Neurology2007https://conductscience.org/library/papers/17151339PubMed
936257298Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.Med2022https://conductscience.org/library/papers/36257298PubMed
1012897283The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.Pediatrics2003https://conductscience.org/library/papers/12897283PubMed
1115711014Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise.J Biol Chem2005https://conductscience.org/library/papers/15711014PubMed
1233601052Centyrin ligands for extrahepatic delivery of siRNA.Mol Ther2021https://conductscience.org/library/papers/33601052PubMed
1337823690Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans.MAbs2023https://conductscience.org/library/papers/37823690PubMed
1421259334Brain glycogen supercompensation in the mouse after recovery from insulin-induced hypoglycemia.J Neurosci Res2011https://conductscience.org/library/papers/21259334PubMed
1526977394Impaired glucose metabolism and exercise capacity with muscle-specific glycogen synthase 1 (gys1) deletion in adult mice.Mol Metab2016https://conductscience.org/library/papers/26977394PubMed
1628895054A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice.Mol Neurobiol2018https://conductscience.org/library/papers/28895054PubMed
1717510371Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model.J Histochem Cytochem2007https://conductscience.org/library/papers/17510371PubMed
1836111639Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism.J Inherit Metab Dis2023https://conductscience.org/library/papers/36111639PubMed
1923457523Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease.PLoS One2013https://conductscience.org/library/papers/23457523PubMed
2016306363Glucose metabolism in mice lacking muscle glycogen synthase.Diabetes2005https://conductscience.org/library/papers/16306363PubMed

See all 30 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42923624Infantile-Onset Pompe Disease: Current Therapeutic Landscape, Clinical Challenges, and Future Horizons.Cureus2026https://conductscience.org/library/papers/42923624PubMed
41948007Unifying the Communities of Early-Onset Glycogen Storage Disease Type IV and Adult Polyglucosan Body Disease Through a Genetic Prevalence Study of GBE1-Related Disease.JIMD Rep2026https://conductscience.org/library/papers/41948007PubMed
41783848Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions.Front Neurol2026https://conductscience.org/library/papers/41783848PubMed
41621836RNA-Based Therapies for Inherited Metabolic Disorders.J Inherit Metab Dis2026https://conductscience.org/library/papers/41621836PubMed
41442049New advances in treating late-onset Pompe Disease: A narrative review.Eur J Pediatr2025https://conductscience.org/library/papers/41442049PubMed
41432033Potent and durable gene modulation in heart and muscle with chemically defined lipophilic siRNAs.Nucleic Acids Res2025https://conductscience.org/library/papers/41432033PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GAA2548PubTator's text mininghttps://conductscience.org/library/genes/2548

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39604266

GET https://conductscience.org/api/papers/v1/39604266/references?page=2